相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group
Verena Ingeborg Gaidzik et al.
BLOOD (2009)
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
David Grimwade et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High EVI1 levels predict adverse outcome in acute myeloid leukemia:: prevalence of EVI1 overexpression. and chromosome 3q26 abnormalities underestimated
Sanne Lugthart et al.
BLOOD (2008)
WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells
Hans J. Stauss et al.
BLOOD CELLS MOLECULES AND DISEASES (2008)
Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker:: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals
Hans Beier Ommen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
Francesco Lo-Coco et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy
Daniela Cilloni et al.
HAEMATOLOGICA (2008)
Mutation of the Wilms' Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party
Priya Virappane et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Development of minimal residual disease-directed therapy in acute myeloid leukemia
Sylvie D. Freeman et al.
SEMINARS IN ONCOLOGY (2008)
Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia:: a trial by the Acute Leukemia French Association (ALFA) Group
X. Thomas et al.
LEUKEMIA (2007)
Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML
K. Summers et al.
LEUKEMIA (2007)
Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia:: biological and clinical implications
C. G. Nyvold et al.
LEUKEMIA (2006)
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
T Büchner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia
H Lapillonne et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia
M Weisser et al.
LEUKEMIA (2005)
Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia
D Osborne et al.
BONE MARROW TRANSPLANTATION (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
WT1 gene expression:: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients -: results from a single-centre study
M Ostergaard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program
E Beillard et al.
LEUKEMIA (2003)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia
M Garg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection
D Cilloni et al.
BLOOD (2003)
The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia
H Ogawa et al.
BLOOD (2003)
Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients
D Cilloni et al.
LEUKEMIA (2002)
Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow
JP van Dijk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Real-time quantitative PCR detection of WT1 gene expression in children with AML:: prognostic significance, correlation with disease status and residual disease detection by flow cytometry
J Trka et al.
LEUKEMIA (2002)
Wilms' tumor gene WT1:: Its oncogenic function and clinical application
H Sugiyama
INTERNATIONAL JOURNAL OF HEMATOLOGY (2001)
分享论文
